Form 4: Halozyme Therapeutics Executive Trades Shares
Statement of Changes in Beneficial Ownership
Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, Inc., reported transactions involving common stock and restricted stock units.
Summary
- Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, Inc., engaged in several transactions on June 12, 2026.
- He acquired 5,034 shares of common stock with no cost, which were part of a restricted stock unit vesting and settlement.
- Following this, he disposed of 2,715 shares of common stock for $69.50 per share, totaling $188,707.50.
- The disposition of 2,715 shares was to cover tax withholding obligations.
- After these transactions, Snyder beneficially owns 49,929 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to compensation and tax obligations rather than a strategic shift or significant investment.
Positives
- Vesting of restricted stock units indicates continued equity compensation for management.
- The acquisition of 5,034 shares through RSU settlement demonstrates a commitment to the company's stock.
Negatives
- Disposition of 2,715 shares to cover tax withholding obligations represents a reduction in direct shareholding.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock dealings. These transactions are common for executives as part of their compensation and tax planning.
Stakeholder Impact
- Shareholders: The filing provides transparency into executive stock ownership changes, which is a standard part of corporate governance.
- Employees: The vesting of restricted stock units may reflect the company's incentive programs for its employees.
Key Dates
| Date | Description |
|---|---|
| 06/12/2026 | Earliest transaction date and date of reported transactions. |
| 06/15/2026 | Date of signature for the filing. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Transaction, Halozyme Therapeutics, Executive Compensation, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.